结肠癌KRAS蛋白磷酸化与化疗抵抗的相关性研究

Correlation of KRAS protein phosphorylation and chemotherapy resistance in colon cancer

目的 :结肠癌是最常见的恶性肿瘤,表皮生长因子受体是结肠癌治疗的靶点。然而耐药性一直是治疗结肠癌的难点。为了减少耐药事件的发生,针对个体化的基因检测将为解决耐药性提供新方案。方法 :收集52例晚期结肠癌临床标本和资料,免疫染色检测了5-FU治疗对抗和不对抗患者中,磷酸化KRAS表达情况。结果 :在5-FU治疗对抗组,磷酸化KRAS表达明显高于正常对照组和不对抗组,具有统计学差异。结论 :磷酸化KRAS表达情况将为晚期结肠癌个体化化疗提供参考。

Objective Colon cancer is the most common malignancy,epidermal growth factor receptor is a target for cancer therapy.However,resistance to the treatment of colon cancer has been difficult.To find a suitable individualized treatment of metastatic colorectal cancer programs to improve the prognosis of metastatic colorectal cancer and minimize the occurrence of adverse drug events,and to provide new solutions for individualized treatment of advanced colorectal cancer.Methods 52 cases of advanced colorectal cancer clinical specimens and data were collected,KRAS phosphorylation was detected by immunostaining in the patients with or without 5-FU resistance.Results phosphorylated KRAS was significantly higher in the patients with 5-FU resistance than the control and the 5-FU un-resistance.Conclusion The expression of phosphorylated KRAS will provide individualized reference in advanced colon cancer chemotherapy.